Literature DB >> 7336429

Hyperornithinemia with gyrate atrophy of the choroid and retina: a disturbance in de novo formation of proline.

T Saito, K Omura, S Hayasaka, H Nakajima, K Mizuno, K Tada.   

Abstract

Two patients with hyperornithinemia and gyrate atrophy of the choroid and retina, the first report in Japan, were described. Serum ornithine was increased 10- to 15-fold and serum lysine was slightly decreased in the affected patients. Urinary excretion of ornithine was also markedly increased. There was no increase in serum proline after the oral loading of ornithine in the patients, whereas serum proline increased after the loading in normal controls. Ornithine-ketoacid transaminase (OKT) activity was markedly reduced in phytohemagglutinin transformed lymphocytes from the patients. In all of their parents and one of the siblings, OKT activity was found to be decreased to about half of the normal control values. These findings indicate that the pathway from ornithine to proline is a major route of ornithine catabolism in man. A possible pathogenesis of ocular disturbance in the patients with OKT deficiency was postulated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7336429     DOI: 10.1620/tjem.135.395

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  3 in total

1.  Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroid and retina.

Authors:  S Hayasaka; T Saito; H Nakajima; O Takahashi; K Mizuno; K Tada
Journal:  Br J Ophthalmol       Date:  1985-04       Impact factor: 4.638

Review 2.  Single amino acid supplementation in aminoacidopathies: a systematic review.

Authors:  Danique van Vliet; Terry G J Derks; Margreet van Rijn; Martijn J de Groot; Anita MacDonald; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2014-01-13       Impact factor: 4.123

3.  Gyrate atrophy-like phenotype with normal plasma ornithine and low plasma taurine.

Authors:  Aubhugn T Labiano; Milagros H Arroyo
Journal:  GMS Ophthalmol Cases       Date:  2020-02-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.